However, the meta-analysis by Mir et al. included 65 patients with OSA and T2DM, and showed that AHI, BMI, and systolic blood pressure (SBP) all decreased and SpO2 increased with SGLT2 inhibition, though these results were not statistically significant [40]. The gene discussed is SLC5A2; the disease is obstructive sleep apnea syndrome.